MindMed to be Included in Russell 2000® and Russell 3000® Indexes
28 Junio 2024 - 6:00AM
Business Wire
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or
"MindMed"), a clinical stage biopharmaceutical company developing
novel product candidates to treat brain health disorders, today
announced today that as part of the annual reconstitution of the
Russell stock indexes, the Company will be included in the Russell
2000® Index and the broad-market Russell 3000® Index, effective
today.
“MindMed’s inclusion in the Russell Indexes mark an exciting
milestone and reflects growing recognition of our commitment to
addressing the unmet medical needs for people with brain health
disorders by advancing MM120 for the treatment of general anxiety
disorder and MM402 for the treatment of autism spectrum disorder,”
said Rob Barrow, Chief Executive Officer of MindMed. “We are
pleased to join the Russell Indexes and look forward to continuing
to share our story with a broader audience of investors.”
Membership in the Russell 3000® Index means automatic inclusion
in the large-cap Russell 1000® Index or small-cap Russell 2000®
Index as well as in the appropriate growth and value style indexes.
The Russell 3000® Index encompasses the 3,000 largest U.S.-traded
stocks by objective, market-capitalization rankings, and style
attributes. Membership in these indexes is updated annually and
remains in place for one year.
The Russell Indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $9.1 trillion in assets
are benchmarked against Russell's U.S. Indexes. Russell Indexes are
part of FTSE Russell, a leading global index provider.
For more information on the Russell Indexes and the Russell U.S.
Indexes Reconstitution, visit the "Russell Reconstitution" section
on the FTSE Russell website.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing
novel product candidates to treat brain health disorders. Our
mission is to be the global leader in the development and delivery
of treatments that unlock new opportunities to improve patient
outcomes. We are developing a pipeline of innovative drug
candidates, with and without acute perceptual effects, targeting
the serotonin, dopamine, and acetylcholine systems.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240628586419/en/
For Media: media@mindmed.co For Investors:
ir@mindmed.co
Mind Medicine MindMed (NASDAQ:MNMD)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Mind Medicine MindMed (NASDAQ:MNMD)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024